(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-1.03%) $82.99
(-1.16%) $1.619
(-0.38%) $2 338.20
(-0.33%) $27.45
(0.51%) $926.80
(-0.13%) $0.933
(-0.11%) $11.01
(-0.20%) $0.799
(0.00%) $92.17
Live Chart Being Loaded With Signals
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders...
Stats | |
---|---|
今日成交量 | 261 676 |
平均成交量 | 261 312 |
市值 | 66.40M |
EPS | $-0.290 ( 2024-04-02 ) |
下一个收益日期 | ( $-0.280 ) 2024-05-06 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -1.230 |
ATR14 | $0.00500 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Sandercock Colin | Buy | 175 000 | Stock Option (right to buy) |
2024-03-06 | Suri Anish | Buy | 300 000 | Stock Option (right to buy) |
2024-03-06 | Millar Kerri-ann | Buy | 250 000 | Stock Option (right to buy) |
2024-03-06 | Passeri Daniel R | Buy | 400 000 | Stock Option (right to buy) |
2024-03-06 | Levisetti Matteo | Buy | 260 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
98.01 |
Last 98 transactions |
Buy: 5 498 246 | Sell: 593 660 |
音量 相关性
Cue Biopharma Inc 相关性 - 货币/商品
Cue Biopharma Inc 财务报表
Annual | 2023 |
营收: | $5.49M |
毛利润: | $2.05M (37.41 %) |
EPS: | $-1.110 |
FY | 2023 |
营收: | $5.49M |
毛利润: | $2.05M (37.41 %) |
EPS: | $-1.110 |
FY | 2022 |
营收: | $1.25M |
毛利润: | $-560 828 (-45.04 %) |
EPS: | $-1.480 |
FY | 2021 |
营收: | $14.94M |
毛利润: | $14.94M (100.00 %) |
EPS: | $-1.410 |
Financial Reports:
No articles found.
Cue Biopharma Inc
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。